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Mast Cell Stabilizing Properties  
of Antihistamines
Francesca Levi-Schaffer1 and Ron Eliashar2
Histamine is a key mediator of allergic inflammation, primarily through com-
petitive antagonism of binding to H1 receptors. In this issue, Weller and Maurer 
report that the H1 antagonist desloratadine possesses mast cell–stabilizing 
properties when challenged in an IgE-dependent or -independent fashion. Thus, 
desloratadine provides benefits that are independent of H1 receptor binding 
and based on mast cell stabilization.
Journal of Investigative Dermatology (2009) 129, 2549-2551. doi:10.1038/jid.2009.256
Histamine
Several mediators are involved in the 
pathophysiology of allergic diseases. 
Among them, histamine is key, espe-
cially in urticaria and rhinitis. Histamine 
was first identified as a mediator of bio-
logical functions in the early 1900s, 
and new roles are still being identi-
fied. Histamine interacts with the four 
histamine receptor subtypes: H1, H2, 
H3, and H4. These G-protein-coupled 
receptors differ in their location, sec-
ond messengers, and histamine-binding 
properties. In allergy—from allergic 
rhinitis and conjunctivitis to urticaria, 
atopic dermatitis, and asthma—the typi-
cal histamine receptor has been thought 
to be H1, and the typical antihistamines 
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have been the H1 antagonists, which 
have been in clinical use for more than 
60 years. Recently, the role of the H4 
receptor in inflammatory and allergic 
diseases has attracted attention (Zampeli 
and Tiligada, 2009).
In the skin, histamine provokes ery-
thema, edema, and itching. In the nose, 
it induces itching, sneezing, edema, 
obstruction, and rhinorrhea. In the lungs, 
it is primarily a broncho constrictor. The 
symptoms of allergic inflammation (AI) 
are produced not only by histamine, but 
also by other inflammatory mediators 
that are released primarily by mast 
cells (MCs) and basophils activated by 
antigen–IgE interactions. Antihistamines 
act through the competitive antagonism/
inverse receptor agonism observed in 
histamine’s binding to H1 receptors on 
nerve endings, smooth muscle, and glan-
dular cells. However, it has long been 
speculated that they might also possess 
anti-inflammatory and MC-stabilizing 
capabilities.
the current evidence
Weller and Maurer (2009, this issue) 
questioned whether desloratadine has 
human skin MC-stabilizing properties. 
Desloratadine, the main metabolite 
of loratadine, is a rapidly active, 
once-daily, nonsedating, selective high-
affinity H1-receptor antagonist/inverse 
receptor agonist that can also interact 
with the five subtypes of muscarinic 
receptors. It has 10–20 times the in vivo 
receptor-binding affinity of loratadine 
and displays linear pharmacokinetics 
after oral administration. It is rapidly 
absorbed and metabolized in its first 
passage through the liver by cytochrome 
P450. Desloratadine has proven efficacy 
and safety in the control of AI symptoms 
attributable to both its anti-H1 proper-
ties and other anti-inflammatory effects.
To study the skin MC-stabilizing 
properties of desloratadine, the authors 
purified human skin MCs and then 
challenged them with anti-IgE antibodies 
or in an IgE-independent fashion with 
substance P or Ca-ionophore. Both 
histamine release and the expression 
of the MC-activating marker, CD107a, 
were evaluated after preincubation with 
and in the subsequent presence of deslo-
ratadine (10-8–10-4 M). Desloratadine 
inhibited both MC activation and 
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CD107 expression in a dose-dependent 
manner, with slight differences among 
the activators. It was therefore concluded 
that desloratadine could be considered 
an effective MC stabilizer. Previously, 
Genovese et al. (1997) demonstrated 
that desloratadine caused concentration-
dependent inhibition of histamine, 
tryptase, LTC4, and PGD2 release from 
human skin MCs challenged with anti-
FcεRI. However, in that study, the MCs 
were only partially purified, and the 
stabilizing effect of the drug could be 
attributed to an indirect effect through 
the contaminating cells, rather than to 
a direct effect on the MCs. The present 
study is important because it provides 
evidence of a direct MC-stabilizing 
property of desloratadine on human 
dermal MCs challenged with both IgE-
dependent and -independent stimuli, 
enhancing the value of this drug in 
treating allergic skin diseases and non-
allergic MC-associated diseases.
anti-H1, antiallergic,  
and mc-stabilizing properties
Anti-H1 drugs such as azatadine, 
cetirizine, mizolastine, and newer 
-generation drugs such as desloratadine, 
fexofenadine, and levocetirizine have 
been shown to have antiallergic/
anti-inflammatory and MC-stabilizing 
properties. The properties of these 
antihistamines and other drugs have been 
extensively summarized and reviewed by 
Assanasen and Naclerio (2000), Agrawal 
(2004), and de Benedictis et al. (2008). 
Importantly, the effects of each drug 
differ quantitatively and qualitatively, 
and they can be both receptor depen-
dent and independent. In vitro, some 
of these drugs may reduce chemotaxis, 
activation, and survival of eosinophils; 
alter the expression of epithelial cell 
adhesion molecules; or alter the pro-
duction of proinflammatory cytokines 
and the Th1/Th2 cytokine balance in 
basophils and T cells. In vivo, adminis-
tering these drugs results in a variety of 
effects. For example, cetirizine reduces 
eosinophil infiltration at the site of aller-
gen challenge in skin, but not in the nose 
(Michel et al., 1988; Klementsson et al., 
1990). On the other hand, mizolastine 
inhibits antigen-induced eosinophil infil-
tration in mouse skin, as well as in the 
nasal cavity of guinea pigs, and reduces 
leukotriene generation (Yamada and 
Funayama, 1998). Mizolastine inhib-
its both the early and the late antigen-
induced soluble ICAM in human skin 
blisters (Michel et al., 2000).
The MC-stabilizing properties of the 
anti-H1 drugs are variable. Okayama 
and colleagues (1994) found that ceti-
rizine inhibited IgE-dependent histamine 
and PGD2 release from lung and tonsil 
MCs, but it exhibited weak inhibitory 
activity on skin MCs, which was not con-
centration dependent. Terfenadine, on 
the other hand, had a dual effect on skin 
MCs; at low concentrations, it exerted a 
concentration-dependent inhibition of 
IgE-dependent histamine release, where-
as at higher concentrations it stimulated 
mediator release. Ketotifen produced 
similar effects (Okayama et al., 1994). 
Nielsen and co-workers (2001) observed 
that cetirizine inhibited in vivo human 
skin reactions but not mediator release 
in immediate allergic cutaneous reac-
tions. They concluded that cetirizine is a 
potent H1-receptor antagonist but that it 
has no effect on MC activation.
Finally, as reviewed by Marshall (2000) 
and Agrawal (2004), desloratadine has 
various anti-inflammatory effects. It 
inhibits ICAM expression in nasal epi-
thelial cells and P-selectin expression 
in umbilical vein epithelium, as well as 
the release of IL-8, RANTES, and soluble 
ICAM from human bronchial epithelial 
cells. Moreover, it decreases the secretion 
of various inflammatory cytokines from 
human leukemic MC and basophil lines 
and, in general, it downregulates many 
immune/inflammatory cell activities, such 
as those of eosinophils and B cells.
Possible mechanisms for desloratadine-
induced mc stabilization
Weller and Maurer (2009) studied 
how desloratadine exerts its inhibitory 
effect on MCs. Different hypotheses 
exist for the mechanisms behind the 
MC-stabilizing properties of antihis-
tamines; these are only suppositions, 
owing to a lack of experimental evi-
dence. Notably, the mechanism of 
action of the “classic” MC-stabilizing 
drug cromolyn sodium remains ill 
defined. Anti-H1 drugs are lipophilic 
cationic compounds that can perme-
ate cell membranes, stabilizing FcεRI 
on MCs and preventing the perturba-
tions otherwise caused by immuno-
logical stimuli. However, Okayama and 
co-workers (1994) found no correla-
tion between the lipophilicity of differ-
ent antihistamines and their inhibitory 
effects on histamine release by MCs. 
Another mechanism of MC stabilization 
may be the direct interference of antihis-
tamines with Ca2+ channels, intracellu-
lar Ca2+ release, and Ca2+ utilization. The 
dissolving of the lipophilic ends of anti-
histamines into cell membranes leads 
to the presentation of a positive charge 
outside of a cell, which can inhibit com-
petitively the binding of Ca2+.
Berthon and colleagues (1994) found 
that loratadine and desloratadine impair 
the increase in Ca2+ that follows cell 
activation by decreasing both the influx 
of extracellular Ca2+ and the release 
of Ca2+ from intracellular stores. The 
reduction of intracellular Ca2+ reduces 
the activity of Ca2+-dependent enzymes, 
such as calmodulin. Indeed, blocking 
of cal modulin in vitro leads to inhibi-
tion of histamine release from MCs 
as a result of a decreased activation of 
enzymes essential for the secretory pro-
cess. Moreover, direct inhibition of cal-
modulin by antihistamines may also lead 
to inhibition of MC-mediator release. 
The degree of inhibition observed with 
desloratadine in Weller and Maurer’s 
study (i.e., around 60% for antigen and 
around 20% for Ca-ionophore) was 
observed in an earlier study using the 
calmodulin antagonist trifluoperazine 
(Chakravarty and Nielsen, 1985). 
However, to the best of our knowledge, 
the direct influence of antihistamines on 
calmodulin has not yet been studied.
Another possible mechanism of MC 
stabilization by desloratadine could be 
the inhibition of autocrine stimulation by 
histamine. Human skin MCs have been 
found to express H1, H2, and H4 but 









In theory, histamine released by MCs 
may bind to H1 receptors on their own 
surface, thereby exerting an autocrine 
amplification of MC-mediator release. 
However, in addition to the weak expres-
sion of H1 receptors on skin MCs, it has 
been shown that preincubation with 
an H1-antagonist caused an increase 
of histamine-induced cAMP on these 
cells, probably because of competitive 
antagonism between H1 and H2 recep-
tors on the same cell. Moreover, hista-
mine seems to have an inhibitory rather 
than an activating effect on MCs via 
H2 receptors in terms of histamine and 
cytokine release. Because histamine may 
exert MC-activating effects by binding to 
H4 receptors, antihistamines could block 
this receptor. Nevertheless, deslorata-
dine—and cetirizine and fexofenadine—
has shown no inhibition of the H4 recep-
tor at concentrations up to 10 µM.
Given the above data, we are tempt-
ed to speculate that desloratadine exerts 
its inhibitory effects on human skin MCs 
by interfering with either intracellular 
Ca2+ accumulation or activation of intra-
cellular Ca2+-dependent enzymes.
The concentrations of deslorata-
dine required to obtain significant 
MC stabilization in this in vitro study 
(10–5–10–4 M) are higher than those 
found in blood (around 10–8 M). It is 
possible that MC-stabilizing effects in 
vivo will be achieved only at higher 
doses. Nevertheless, Frossard and col-
leagues (2008) were recently able to 
detect more than 100-fold higher con-
centrations of desloratadine in skin 
than in plasma.
conclusions
It is clear that desloratadine and other 
H1 antagonists provide beneficial 
effects in AI that are not directly H1 
receptor binding–linked and are gener-
ally based on anti-inflammatory prop-
erties and inhibition of MC/basophil 
histamine release.
Weller and Maurer’s study supports 
an in vitro (and possibly in vivo) role for 
desloratadine as a skin MC stabilizer. 
The mechanisms by which desloratadine 
and other antihistamines act as MC 
stabilizers are not yet identified, but 
they are likely concentration dependent 
and diverse. Ad hoc in vitro mechan-
istic studies are needed to define the 
MC-stabilizing properties of these drugs.
The in vitro concentrations of deslo-
ratadine required to achieve MC 
stabilization are considerably higher 
than those achieved at therapeutic doses. 
It has not been established whether the 
antiallergic/anti-inflammatory properties 
described in vitro and in animal models 
exist in humans, nor has the mechan-
ism of action or its clinical significance 
been determined. To provide a definite 
answer, the antiallergic/anti-inflammatory 
and MC-stabilizing properties of 
antihistamines should be demonstrated 
in vivo, in allergic patients, and at 
therapeutic and safe doses.
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